Glenview Trust Co Increases Stake in IDEXX Laboratories, Inc. $IDXX

Glenview Trust Co raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,729 shares of the company’s stock after acquiring an additional 2,312 shares during the quarter. Glenview Trust Co owned approximately 0.05% of IDEXX Laboratories worth $26,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. STF Management LP grew its holdings in IDEXX Laboratories by 1.3% during the second quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares during the period. Clearstead Trust LLC raised its stake in shares of IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of IDEXX Laboratories by 4.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after buying an additional 16 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 3.3% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after buying an additional 17 shares in the last quarter. Finally, Stratos Wealth Partners LTD. grew its stake in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after acquiring an additional 18 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. JPMorgan Chase & Co. upped their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Performance

IDXX opened at $629.35 on Tuesday. The stock has a market capitalization of $50.25 billion, a price-to-earnings ratio of 48.15, a PEG ratio of 3.83 and a beta of 1.67. The company has a fifty day moving average of $683.44 and a 200 day moving average of $669.02. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.